| | |
C.R. Sukumar 09:25 PM | October 23,2009
Dr Reddy’s also benefited from foreign exchange gains, low amortization and low interest costs
|
|
Lawfully Yours | AZB and Partners 10:20 PM | October 11,2009
Bayer contended DCGI should not approve any application for a generic drug if the original has been patented
|
|
PTI 12:09 PM | October 04,2009
Indian entities listed on the New York Stock Exchange and Nasdaq added $3.56 billion to their market-cap, with Wipro and ICICI Bank together contributing $3.15 billion
|
|
Reuters 04:40 PM | September 18,2009
The 30-share BSE index ended 30.19 higher at 16,741.30, with 17 stocks rising
|
|
06:29 PM | September 14,2009
Companies may be replacing IPOs with something better; Fortis plans to unveil its Rs1,000 crore rights issues by October; Dr Reddy’s Laboratories launches generic version of a Novartis drug in the US
|
|
PTI 03:37 PM | August 05,2009
The product is licensed from Sparsha pharma and is the first opiod transdermal patch to be developed in India
|
|
Bharghavi Nagaraju / Reuters 05:40 PM | July 22,2009
Sees FY10 EPS at Rs24; 16% revenue growth; sees muted contract manufacturing business for 6-9 months
|
|
C.R. Sukumar 12:25 AM | January 20,2009
Dr Reddy’s acquired a Satyam subsidiary that owned 134 acres near Hyderabad; now state stakes claim to the land
|
|
Mrinalini Datta 12:34 AM | May 21,2008
Dr Reddy’s sales in North America, mainly the US, declined to Rs250 crore from Rs560 crore a year earlier
|
|
C.R. Sukumar and Bhuma Shrivastava 11:51 PM | January 25,2008
The Hyderabad firm also suffered from reduced generic drug prices and increasing rebates to insurers
FIND MORE ARTICLES ON:
Dr Reddy DrugsQ3
|
|
Bhuma Shrivastava 11:27 PM | January 15,2008
A stronger rupee, which has appreciated some 14% since January last year, continued to dampen drugs exports
|
|
PTI 04:54 PM | November 26,2007
This is a big milestone in the development programme targeting a novel disease-modifying approach to treat the underlying cause of certain chronic respiratory disease
|
|
C.R. Sukumar and Bhuma Shrivastava 12:26 AM | October 25,2007
Subsidiary Betapharm also posted a 12% sales decline because of a supply crunch and the appreciating rupee
FIND MORE ARTICLES ON:
Lower genericsDr Reddy
|
|
Bhuma Shrivastava 01:04 AM | May 24,2007
The safety debate may take the sheen off a patent suit; could make a dud of a molecule in its laboratories
|
|